News
ENLIGHTEN 2 trial met primary endpoint with LYR-210 demonstrating statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at 24 weeks (p=0.0078)ENLIGHTEN ...
The ENLIGHTEN 2 study met its primary goal, showing statistically significant improvement in chronic rhinosinusitis (CRS) symptoms at 24 weeks. The therapy helped reduce nasal obstruction ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback